Evaluation of regorafenib in colorectal cancer and GIST. (Q46542250)

23 December 2017

title

Evaluation of regorafenib in colorectal cancer and GIST. (English)

1 reference

23 December 2017

1 reference

2

1 reference

23 December 2017

author name string

Tom Waddell

series ordinal

1

1 reference

23 December 2017

language of work or name

English

0 references

publication date

22 November 2012

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

381

1 reference

23 December 2017

issue

9863

1 reference

23 December 2017

page(s)

273-275

1 reference

23 December 2017

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

1 reference

7 January 2021

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962006-6

7 January 2021

10.1016/S0140-6736(12)62006-6

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017